RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy A Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Debora Fumagalli; David Venet; Michail Ignatiadis; Hatem A Azim; Marion Maetens; Francoise Rothe; Roberto Salgado; Ian Bradbury; Lajos Pusztai; Nadia Harbeck; Henry Gomez; Tsai-Wang Chang; Maria Antonia Coccia-Portugal; Serena Di Cosimo; Evandro de Azambuja; Lorena de la Pena; Paolo Nuciforo; Jan C Brase; Jens Huober; Jose Baselga; Martine Piccart; Sherene Loi; Christos Sotiriou

Journal article

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy A Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Debora Fumagalli, David Venet, Michail Ignatiadis, Hatem A Azim, Marion Maetens, Francoise Rothe, Roberto Salgado, Ian Bradbury, Lajos Pusztai, Nadia Harbeck, Henry Gomez, Tsai-Wang Chang, Maria Antonia Coccia-Portugal, Serena Di Cosimo, Evandro de Azambuja, Lorena de la Pena, Paolo Nuciforo, Jan C Brase, Jens Huober, Jose Baselga Show all

JAMA Oncology | AMER MEDICAL ASSOC | Published : 2017

DOI: 10.1001/jamaoncol.2016.3824

University of Melbourne Researchers

Sherene Loi Author The Sir Peter MacCallum Department of Oncology

Grants

Funding Acknowledgements

The NeoALTTO study and this substudy were sponsored by GlaxoSmithKline; lapatinib is an asset of Novartis AG as of March 2, 2015. Dr Venet's activity is partly supported by a grant of the Region Wallonne.